• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: LIVANOVA CANADA CORP PERCEVAL S HEART VALVE; TISSUE HEART VALVE

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

LIVANOVA CANADA CORP PERCEVAL S HEART VALVE; TISSUE HEART VALVE Back to Search Results
Model Number PVS23
Device Problems Perivalvular Leak (1457); Malposition of Device (2616); Device Dislodged or Dislocated (2923)
Patient Problem No Information (3190)
Event Date 07/02/2018
Event Type  Injury  
Manufacturer Narrative
The initial malpositioning of the device can be attributed to user error, and may also be related to a failure to follow the instructions for use, given that the guiding sutures were held by a tourniquet which is not indicated in the ifu.The observed paravalvular leak can reasonably be attributed to bulky calcium in the patient annulus which was removed aver re-opening the aortotomy, given that the device was ultimately implanted successfully without any paravalvular leak.The perceval ifu explicitly states that bulky or protruding calcium must be removed prior to implant.Therefore, the failure to remove such calcium is considered a failure to follow the instructions for use.The subsequent dislodgement during the de-airing process can reasonably be attributed to the manipulation of the heart.It is explicitly stated in the instructions for use that care must be taken if manipulation of the heart is required, as this may lead to dislodgement of the valve.Based on the information provided, the device was ultimately implanted successfully.As such, no device issue is suspected.The reported event can reasonably be attribute to user error and a failure to follow the instructions for use, as discussed above.Not explanted.
 
Event Description
An pvs23 was implanted during an isolated avr.The patient's annulus was decalcified and the valve was sized for a pvs23.The valve was collapsed and parachuted into place.The guiding sutures were held in place using tourniquets, not according to the ifu.The valve was positioned to high, so it was removed and re-collapsed against the ifu.The valve was re-implanted, this time with an assistant holding the guiding sutures.The surgeon ballooned the valve at 3 atm (off-label), and warm saline was applied.The aortotomy was closed and the patient was weaned from bypass.On echo, the placement of the valve was correct.A small paravalvular leak was identified on the non-coronary side where there was previously a large bulk of calcium.After de-airing, the valve migrated into the sinuses and a paravalvular and central leak were observed.The heart was reportedly manipulated during the de-airing process which could have led to the observed dislodgement.Cardiopulmonary bypass was resumed and the aortotomy was re-opened.Visual inspection confirmed that the valve was too high, as indicated by echo.The valve was once again removed, and further decalcification was performed where the initial paravalvular leak was identified.The valve was re-collapsed and re-implanted, with an assistant holding the guiding sutures.Visual inspection confirmed the appropriate placement of the valve, and good coaptation.The vale was ballooned for 30 seconds at 4 atm, and warm saline was applied.The aortotomy was closed, and the patient was weaned from bypass.Echo confirmed appropriate valve placement, and no leaks were identified.The mean gradient was 5 mmhg.The first and second cross-clamp times were 84 minutes and 60 minutes, respectively.The patient is doing well, with good sinus rhythm and function post-operatively.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PERCEVAL S HEART VALVE
Type of Device
TISSUE HEART VALVE
Manufacturer (Section D)
LIVANOVA CANADA CORP
5005 north fraser way
burnaby, bc V5J5M 1
CA  V5J5M1
Manufacturer (Section G)
LIVANOVA CANADA CORP
5005 north fraser way
burnaby, bc V5J5M 1
CA   V5J5M1
Manufacturer Contact
francesca crovato
5005 north fraser way
burnaby, bc V5J5M-1
CA   V5J5M1
MDR Report Key7727935
MDR Text Key115277539
Report Number3004478276-2018-00265
Device Sequence Number1
Product Code LWR
UDI-Device Identifier00896208000429
UDI-Public(01)00896208000429(240)ICV1209(17)201116
Combination Product (y/n)N
Reporter Country CodeUS
PMA/PMN Number
P150011
Number of Events Reported1
Summary Report (Y/N)N
Report Source Manufacturer
Source Type company representative,health
Reporter Occupation Physician
Type of Report Initial
Report Date 07/27/2018
1 Device was Involved in the Event
1 Patient was Involved in the Event
Date FDA Received07/27/2018
Is this an Adverse Event Report? Yes
Is this a Product Problem Report? No
Device Operator Health Professional
Device Expiration Date11/16/2020
Device Model NumberPVS23
Device Catalogue NumberICV1208
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? No
Date Manufacturer Received07/02/2018
Was Device Evaluated by Manufacturer? Device Not Returned to Manufacturer
Date Device Manufactured11/16/2017
Is the Device Single Use? Yes
Is This a Reprocessed and Reused Single-Use Device? No
Type of Device Usage Initial
Patient Sequence Number1
Patient Outcome(s) Required Intervention;
Patient Age84 YR
-
-